Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-11-26
pubmed:abstractText
Selenium is a central determinant of antioxidative glutathione peroxidase 1 (GPx-1) expression and activity. The relevance of selenium supplementation on GPx-1 in coronary artery disease (CAD) needs to be established. We assessed the effect of selenium supplementation on GPx-1 in cell culture and on endothelial function in a prospective clinical trial.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1097-6744
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
156
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1201.e1-11
pubmed:meshHeading
pubmed-meshheading:19033020-Aged, pubmed-meshheading:19033020-Antioxidants, pubmed-meshheading:19033020-Coronary Artery Disease, pubmed-meshheading:19033020-Coronary Vessels, pubmed-meshheading:19033020-Cysteine, pubmed-meshheading:19033020-Dose-Response Relationship, Drug, pubmed-meshheading:19033020-Endothelium, Vascular, pubmed-meshheading:19033020-Erythrocytes, pubmed-meshheading:19033020-Female, pubmed-meshheading:19033020-Glutathione Peroxidase, pubmed-meshheading:19033020-Humans, pubmed-meshheading:19033020-Male, pubmed-meshheading:19033020-Middle Aged, pubmed-meshheading:19033020-Organoselenium Compounds, pubmed-meshheading:19033020-Prospective Studies, pubmed-meshheading:19033020-Selenomethionine, pubmed-meshheading:19033020-Sodium Selenite, pubmed-meshheading:19033020-Vasodilation
pubmed:year
2008
pubmed:articleTitle
Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease The SElenium Therapy in Coronary Artery disease Patients (SETCAP) Study.
pubmed:affiliation
Department of Medicine II, Johannes Gutenberg-University, Mainz, Germany.
pubmed:publicationType
Journal Article, Comparative Study, In Vitro, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Research Support, N.I.H., Extramural